[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1970

Psoriasis, Methotrexate, and Cirrhosis

Author Affiliations

Mayo Clinic Rochester, Minn 55901

Arch Dermatol. 1970;101(4):379. doi:10.1001/archderm.1970.04000040001001

When given orally or intramuscularly in relatively low dosages methotrexate, a folic acid antagonist, can effectively suppress the signs and symptoms of psoriasis. But it neither cures the disease nor induces remissions in most cases. Physicians first used the drug only in severe incapacitating forms of psoriasis such as erythroderma, generalized pustular psoriasis, or other totally disabling psoriatic disease; now indications are expanding to include milder degrees of involvement where only cosmetic inconvenience exists.

Folic acid antagonists seem to exert their beneficial effects, both on benign and malignant diseases, by suppressing nucleic acid synthesis and preventing cell duplication; and these effects are exaggerated in rapidly dividing tissues such as those of the bone marrow, gastrointestinal epithelium, hair matrix, testis, and fetal tissues, as well as in psoriatic epidermis and in selected primitive and rapidly growing cancers. Methotrexate also has poorly delineated immunosuppressive and antiinflammatory actions which are not understood. Recently,

First Page Preview View Large
First page PDF preview
First page PDF preview